Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) shot up 4.3% during trading on Monday . The stock traded as high as $422.47 and last traded at $421.60, with a volume of 567,128 shares traded. The stock had previously closed at $404.30.

Several brokerages have recently commented on REGN. Leerink Swann reissued a “buy” rating and set a $530.00 price target (up previously from $523.00) on shares of Regeneron Pharmaceuticals in a research note on Sunday, May 8th. Piper Jaffray Cos. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Sunday, May 8th. RBC Capital Markets reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Saturday, August 6th. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 10th. Finally, Vetr lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating and set a $422.08 target price on the stock. in a research note on Wednesday, July 27th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and thirteen have issued a buy rating to the company. Regeneron Pharmaceuticals has a consensus rating of “Hold” and an average target price of $477.00.

The stock has a market capitalization of $43.75 billion and a P/E ratio of 65.2326. The firm’s 50-day moving average price is $399.57 and its 200-day moving average price is $388.54.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.17. During the same period in the prior year, the business posted $2.89 EPS. The firm earned $1.21 billion during the quarter, compared to analyst estimates of $1.24 billion. The company’s revenue for the quarter was up 21.4% on a year-over-year basis. Equities analysts predict that Regeneron Pharmaceuticals Inc. will post $10.95 earnings per share for the current year.

In related news, major shareholder Sanofi bought 64,731 shares of the firm’s stock in a transaction on Tuesday, June 14th. The stock was bought at an average price of $363.86 per share, with a total value of $23,553,021.66. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Joseph L. Goldstein sold 2,125 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, July 29th. The shares were sold at an average price of $425.00, for a total transaction of $903,125.00. Following the sale, the director now directly owns 15,125 shares of the company’s stock, valued at approximately $6,428,125. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have added to or reduced their stakes in the stock. Victory Capital Management Inc. increased its position in Regeneron Pharmaceuticals by 106.2% in the fourth quarter. Victory Capital Management Inc. now owns 2,072 shares of the biopharmaceutical company’s stock worth $1,125,000 after buying an additional 1,067 shares in the last quarter. US Bancorp DE increased its position in Regeneron Pharmaceuticals by 9.4% in the fourth quarter. US Bancorp DE now owns 3,975 shares of the biopharmaceutical company’s stock worth $2,158,000 after buying an additional 340 shares in the last quarter. I.G. Investment Management LTD. increased its position in Regeneron Pharmaceuticals by 1.3% in the fourth quarter. I.G. Investment Management LTD. now owns 20,090 shares of the biopharmaceutical company’s stock worth $10,906,000 after buying an additional 264 shares in the last quarter. Stephens Inc. AR increased its position in Regeneron Pharmaceuticals by 8.3% in the fourth quarter. Stephens Inc. AR now owns 2,488 shares of the biopharmaceutical company’s stock worth $1,351,000 after buying an additional 190 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Regeneron Pharmaceuticals by 5.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 136,447 shares of the biopharmaceutical company’s stock worth $74,078,000 after buying an additional 7,316 shares in the last quarter.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.